Literature DB >> 27644763

Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges.

Karolina Okła1, Iwona Wertel1, Grzegorz Polak1, Justyna Surówka1, Anna Wawruszak2, Jan Kotarski1.   

Abstract

Cancers are complex masses of malignant cells and nonmalignant cells that create the tumor microenvironment (TME). Non-transformed cells of the TME such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) have been observed in the TME of ovarian cancer (OC) patients. Although these subsets may contribute to each step of carcinogenesis and are commonly associated with poor prognosis, still little is known about creation of the protumor microenvironment in OC. In this review, we focused on the nature and prognostic significance of TAMs and MDSCs in OC patients. Moreover, we discuss the main problems and challenges that must be overcome by researchers and clinicians to enrich our knowledge about the immunosuppressive microenvironment of cancers.

Entities:  

Keywords:  Ovarian cancer; myeloid-derived suppressor cells; tumor microenvironment; tumor-associated macrophages

Mesh:

Year:  2016        PMID: 27644763     DOI: 10.1080/08830185.2016.1206097

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  14 in total

1.  Identification of CD8+ T Cell Related Biomarkers in Ovarian Cancer.

Authors:  Ling Li; Dian Chen; Xiaolin Luo; Zhengkun Wang; Hanjie Yu; Weicheng Gao; Weiqiang Zhong
Journal:  Front Genet       Date:  2022-05-27       Impact factor: 4.772

2.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Potential Roles of Peripheral Dopamine in Tumor Immunity.

Authors:  Xiang Zhang; Qiaofei Liu; Quan Liao; Yupei Zhao
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

4.  Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.

Authors:  Karolina Okła; Arkadiusz Czerwonka; Anna Wawruszak; Marcin Bobiński; Monika Bilska; Rafał Tarkowski; Wiesława Bednarek; Iwona Wertel; Jan Kotarski
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

5.  The omentum, a niche for premetastatic ovarian cancer.

Authors:  Xiaojing Ma
Journal:  J Exp Med       Date:  2020-04-06       Impact factor: 14.307

6.  Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.

Authors:  Karolina Okła; Alicja Rajtak; Arkadiusz Czerwonka; Marcin Bobiński; Anna Wawruszak; Rafał Tarkowski; Wiesława Bednarek; Justyna Szumiło; Jan Kotarski
Journal:  J Transl Med       Date:  2020-06-01       Impact factor: 5.531

Review 7.  The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.

Authors:  Galaxia M Rodriguez; Kristianne J C Galpin; Curtis W McCloskey; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-24       Impact factor: 6.639

Review 8.  Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics.

Authors:  Curtis W McCloskey; Galaxia M Rodriguez; Kristianne J C Galpin; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-26       Impact factor: 6.639

Review 9.  Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Cancers (Basel)       Date:  2018-09-01       Impact factor: 6.639

Review 10.  Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods.

Authors:  Nuzhat Ahmed; Elif Kadife; Ali Raza; Mary Short; Paul T Jubinsky; George Kannourakis
Journal:  Cells       Date:  2020-03-14       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.